Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Related Research Peptides Important: Supplied strictly for research use only
Research Highlights Phase 1 (12 weeks): Reductions between ~2.6% and ~11.3% Phase 2 (48 weeks): Lower-dose groups reached ~9% reductions Higher-dose and titration groups achieved ~20% reductions Control groups saw ~0.4% These outcomes place Eloralintide among the strongest-performing compounds within the amylin-pathway category
2% GHK-CU (Copper Tripeptide-1) Clinically tested at 0.1% concentration, it increased collagen production by 51%, skin firmness by 25%, and skin density by 23%, in 84 days
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 digital issues and online access to articles 133,45 per year only 11,12 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
US$ 23.82
US$ 23.73
US$ 25.94
US$ 29.26
US$ 24.57
US$ 20.88
US$ 20.70
US$ 20.78
US$ 20.33